New five year plan for Australian pharma industry

9 May 2017
australia_big

The Australian government has reached a major agreement with the pharmaceutical industry related to drug prices and the Pharmaceutical Benefits Scheme (PBS).

Trade group Medicines Australia says the new agreement will deliver A$1.8 billion ($1.3 billion) in savings, which will be reinvested into the supply of medicines, including more breakthrough therapies listed on the PBS.

The government-run program, which enables patients to buy a wide range of prescription drugs at a subsidized price, has in recent years been expanded to include more medicines, with further cost reductions for patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical